Pierre-Yves Dumas
0000-0003-0119-3548
8 papers found
Refreshing results…
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
Overlapping features of therapy-related and de novo NPM1-mutated AML
Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Missing publications? Search for publications with a matching author name.